A number of characteristics distinguish TETS and organophosphorus (OPs) cholinesterase inhibitors as credible chemical threat agents. 1) These agents can be easily manufactured on a large scale. 2) They are widely available in some countries even though banned in the US. 3) Exposure to either TETS or OPs dose dependently results in lethality or profound and sustained damage to the brain. In rodents, acute TETS or OP intoxication elicits delayed neuronal injury as evidenced by increased apoptosis and oxidative stress in the CNS that persists for up to several days following exposure. In humans, indivuduals that survive acute TETS or OP intoxication often experience significant brain damage. A limited number of therapeutic agents are available to prevent mortality induced by OP threat agents but these do not sufficiently protect against brain injury. Therapeutic approaches for TETS intoxication are less well known. To address these gaps, Core B will synthesize TETS and an inactive analog to be used as a negative control in mechanistic studies, as well as characterize and validate primary standard stocks of TETS, DFP and parathion. This will enable Projects 1-3 to advance applied therapeutic and mechanistic knowledge on these agents. Furthermore we will synthesize, characterize, test and optimize the pharmacokinetic (PK) properties and CNS penetration of two distinct classes of therapeutic agents, sEH inhibitors and KCa2 channel activators. Overall, the successful realization of the proposed aims in Core B is likely to improve therapeutic approaches for the treatment of acute OP and TETS intoxication by providing novel therapeutics for physicians and emergency first-responders to effectively intervene in cases of human intoxication with these seizurogenic chemical threat agents.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
5U54NS079202-03
Application #
8730735
Study Section
Special Emphasis Panel (ZRG1-MDCN-J)
Project Start
Project End
Budget Start
2014-09-01
Budget End
2015-08-31
Support Year
3
Fiscal Year
2014
Total Cost
$415,777
Indirect Cost
$143,245
Name
University of California Davis
Department
Type
DUNS #
047120084
City
Davis
State
CA
Country
United States
Zip Code
95618
Tu, Ranran; Armstrong, Jillian; Lee, Kin Sing Stephen et al. (2018) Soluble epoxide hydrolase inhibition decreases reperfusion injury after focal cerebral ischemia. Sci Rep 8:5279
Hampe, Alexander E; Li, Zidong; Sethi, Sunjay et al. (2018) A Microfluidic Platform to Study Astrocyte Adhesion on Nanoporous Gold Thin Films. Nanomaterials (Basel) 8:
Hobson, Brad A; Rowland, Douglas J; Supasai, Suangsuda et al. (2018) A magnetic resonance imaging study of early brain injury in a rat model of acute DFP intoxication. Neurotoxicology 66:170-178
Moeller, Benjamin; Espelien, Brenna; Weber, Waylon et al. (2018) The pharmacokinetics of ketamine following intramuscular injection to F344 rats. Drug Test Anal :
Pressly, Brandon; Nguyen, Hai M; Wulff, Heike (2018) GABAA receptor subtype selectivity of the proconvulsant rodenticide TETS. Arch Toxicol 92:833-844
Dhir, Ashish; Rogawski, Michael A (2018) Determination of minimal steady-state plasma level of diazepam causing seizure threshold elevation in rats. Epilepsia 59:935-944
Kodani, Sean D; Barthélemy, Morgane; Kamita, Shizuo G et al. (2017) Development of amide-based fluorescent probes for selective measurement of carboxylesterase 1 activity in tissue extracts. Anal Biochem 539:81-89
Barnych, Bogdan; Rand, Amy A; Cajka, Tomas et al. (2017) Synthesis of cyclooxygenase metabolites of 8,9-epoxyeicosatrienoic acid (EET): 11- and 15-hydroxy 8,9-EETs. Org Biomol Chem 15:4308-4313
Vasylieva, Natalia; Barnych, Bogdan; Wan, Debin et al. (2017) Hydroxy-fipronil is a new urinary biomarker of exposure to fipronil. Environ Int 103:91-98
Wagner, Karen M; McReynolds, Cindy B; Schmidt, William K et al. (2017) Soluble epoxide hydrolase as a therapeutic target for pain, inflammatory and neurodegenerative diseases. Pharmacol Ther 180:62-76

Showing the most recent 10 out of 85 publications